Carcinoma, Non-Small-Cell Lung
"Carcinoma, Non-Small-Cell Lung" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
Descriptor ID |
D002289
|
MeSH Number(s) |
C04.588.894.797.520.109.220.249 C08.381.540.140.500 C08.785.520.100.220.500
|
Concept/Terms |
Carcinoma, Non-Small-Cell Lung- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Non Small Cell Lung
- Carcinomas, Non-Small-Cell Lung
- Lung Carcinoma, Non-Small-Cell
- Lung Carcinomas, Non-Small-Cell
- Non-Small-Cell Lung Carcinomas
- Nonsmall Cell Lung Cancer
- Non-Small-Cell Lung Carcinoma
- Non Small Cell Lung Carcinoma
- Carcinoma, Non-Small Cell Lung
- Non-Small Cell Lung Cancer
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Non-Small-Cell Lung".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Non-Small-Cell Lung".
This graph shows the total number of publications written about "Carcinoma, Non-Small-Cell Lung" by people in this website by year, and whether "Carcinoma, Non-Small-Cell Lung" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 5 | 3 | 8 |
1995 | 7 | 2 | 9 |
1996 | 4 | 0 | 4 |
1997 | 4 | 0 | 4 |
1998 | 10 | 1 | 11 |
1999 | 4 | 0 | 4 |
2000 | 5 | 2 | 7 |
2001 | 6 | 2 | 8 |
2002 | 6 | 1 | 7 |
2003 | 17 | 1 | 18 |
2004 | 8 | 1 | 9 |
2005 | 13 | 5 | 18 |
2006 | 13 | 4 | 17 |
2007 | 19 | 2 | 21 |
2008 | 17 | 4 | 21 |
2009 | 16 | 3 | 19 |
2010 | 19 | 3 | 22 |
2011 | 37 | 4 | 41 |
2012 | 26 | 0 | 26 |
2013 | 33 | 1 | 34 |
2014 | 21 | 3 | 24 |
2015 | 44 | 2 | 46 |
2016 | 37 | 3 | 40 |
2017 | 32 | 2 | 34 |
2018 | 43 | 4 | 47 |
2019 | 44 | 3 | 47 |
2020 | 52 | 2 | 54 |
2021 | 45 | 3 | 48 |
2022 | 38 | 0 | 38 |
2023 | 39 | 0 | 39 |
2024 | 6 | 0 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoma, Non-Small-Cell Lung" by people in Profiles.
-
Facts and Hopes in Neoadjuvant Immunotherapy: Current Approvals and Emerging Evidence. Clin Cancer Res. 2024 Apr 01; 30(7):1232-1239.
-
Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer. J Med Econ. 2024 Jan-Dec; 27(1):292-303.
-
Association between reproductive factors with lung cancer incidence and mortality: A pooled analysis of over 308,000 females in the Asia cohort consortium. Int J Cancer. 2024 Jun 15; 154(12):2090-2105.
-
Transfer Learning for Mortality Prediction in Non-Small Cell Lung Cancer with Low-Resolution Histopathology Slide Snapshots. Stud Health Technol Inform. 2024 Jan 25; 310:735-739.
-
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients. Eur J Cancer. 2024 Mar; 199:113530.
-
Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy. J Exp Clin Cancer Res. 2024 Jan 02; 43(1):6.
-
Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT). Lung Cancer. 2024 01; 187:107441.
-
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial. J Clin Oncol. 2024 Jan 10; 42(2):192-204.
-
Identification of Candidate mRNA Genes and Their Potential MicroRNA Targets in Lung Cancer Induced by Smoking Tobacco. Front Biosci (Schol Ed). 2023 11 27; 15(4):13.
-
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B. Cell Rep Med. 2023 11 21; 4(11):101280.